LegoChem Biosciences and Glycotope announce research collaboration and license agreement for an antibody for use as antibody drug conjugate


Seoul, South Korea, and Berlin, Germany – (July 12, 2022) – LegoChem Biosciences Inc. (LCB) and Glycotope GmbH (Glycotope) have signed a Research Collaboration and License Agreement to develop an antibody drug conjugate (ADC) by combining LCB’s proprietary ADC technology with one of Glycotope’s investigational tumor targeting antibodies.

Under the terms of the agreement LCB has the right to exercise its option for worldwide exclusive rights to develop and commercialize the selected antibody as ADC, upon successful completion of a feasibility study. If LCB exercises these rights, Glycotope will receive an upfront payment as well as development and sales milestone payments plus royalties. Specific financial terms have not been disclosed.

“Through this collaboration, once the candidate ADC is discovered and nominated, Glycotope and LCB plan to advance this very innovative program to clinical stage as a competitive cancer therapy,” said Dr. Yong-Zu Kim, CEO & President of LCB. “We are very pleased that companies with innovative antibody platforms, such as Glycotope have recognized the advantages of LCB’s linker-payload technology, which has been proven to be plasma stable as well as cancer-selectively activated.”

“This exciting collaboration with LegoChem further underlines the value of Glycotope’s unique technology platform and strengthens our leading position in the development of highly specific glyco-epitope targeting antibodies,” added Henner Kollenberg, CEO, Glycotope.  

“Our antibodies are designed to deliver increased tumor selectivity. Combining these with LCB’s ADC technology platform offers the opportunity to develop ADCs with potential to perform beyond today’s best standard of care,” said Patrik Kehler, CSO, Glycotope. 

ADCs are a type of targeted cancer medicine that deliver cytotoxic chemotherapy (“payload”) to cancer cells via a linker attached to a monoclonal antibody that binds to a specific target expressed on cancer cells. LCB’s ADC platform technologies overcome the existing limitations of ADCs by imparting a trinity of improved properties, (1) site-specific stable bioconjugation (2) cancer selective linker activation and (3) cancer-selective activation of potent payload, all of which in a significantly broader Therapeutic Window.

Glycotope’s antibodies target specific tumor-associated carbohydrate structures or protein/carbohydrate combined glyco-epitopes (GlycoTargets). Targeting these specific antigens enables broad indication range, long-term treatment potential and reduced on-target/off tumor toxicity, key elements of highly potent therapies. Based on this unrivalled tumor-specificity, Glycotope’s antibodies are highly suitable for a multi-function platform approach with independent modes of action to provide a tailored therapy format for as many patients as possible.

Contact Information:

LegoChem Biosciences

Media Contact:

Dae-Young Jeong, Investor Relations
Phone: +82-42-861-0688

Glycotope GmbH

Henner Kollenberg (CEO)
Phone: +49 30 9489 2600

Media Contact:

Chris Gardner, Chris Welsh
Consilium Strategic Communications
Phone: +44 20 3709 5700

About LegoChem Biosciences

LegoChem Biosciences (LCB, KOSDAQ: 141080) is a clinical-stage biopharmaceutical company focusing on the development of next-generation novel therapeutics utilizing its proprietary medicinal drug discovery technology LegoChemistry and ADC platform technology ConjuAll Since its foundation in 2006, LCB has focused on the research and development of Antibody-Drug-Conjugates (ADCs), antibiotics, anti-fibrotic and anticancer therapeutics based on proprietary platform technologies. 

About Glycotope

Glycotope is a biotechnology company utilizing a proprietary technology platform to develop uniquely tumor-specific monoclonal antibodies. We combine expertise in glycobiology and antibody development to advance first-in-class therapeutics for oncology. Our antibodies target specific tumor-associated carbohydrate structures or protein/carbohydrate combined glyco-epitopes (GlycoTargets). Based on their superior tumor-specificity, our antibodies are suitable for development in an array of different modes of action including naked antibodies, bispecifics, antibody-drug-conjugates, cellular therapies or fusion-proteins. Glycotope has to date discovered more than 200 GlycoTargets with antibodies against several of these targets currently under development. Visit